Hydrophilically modified self-assembling α-tocopherol derivative as niosomal nanocarrier for improving clarithromycin oral bioavailability

References

• Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.
   PubMed Web of Science ®Google Scholar
• Avdeef A. Absorption and drug development: solubility, permeability, and charge state. Hoboken (NJ): John Wiley & Sons; 2012.
   Google Scholar
• Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev. 1997;25:103–128.
   Web of Science ®Google Scholar
• Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727.
   PubMedGoogle Scholar
• Safari J, Zarnegar Z. Advanced drug delivery systems: nanotechnology of health design. A review. J Saudi Chem Soc. 2014;18:85–99.
   Web of Science ®Google Scholar
• Ye L, Zhang Y, Yang B, et al. Zwitterionic-modified starch-based stealth micelles for prolonging circulation time and reducing macrophage response. ACS Appl Mater Interfaces. 2016;8:4385–4398.
   PubMed Web of Science ®Google Scholar
• Rajera R, Nagpal K, Singh SK, et al. Niosomes: a controlled and novel drug delivery system. Biol Pharm Bull. 2011;34:945–953.
   PubMed Web of Science ®Google Scholar
• Singh D, Pradhan M, Nag M, et al. Vesicular system: versatile carrier for transdermal delivery of bioactives. Artif Cells Nanomed Biotecnol. 2015;43:282–290.
   PubMed Web of Science ®Google Scholar
• Escudero I, Geanta RM, Ruiz MO, et al. Formulation and characterization of Tween 80/cholesterol niosomes modified with tri-n-octylmethylammonium chloride (TOMAC) for carboxylic acids entrapment. Colloids Surf A. 2014;461:167–177.
   Web of Science ®Google Scholar
• Tavano L, Muzzalupo R, Picci N, et al. Co-encapsulation of lipophilic antioxidants into niosomal carriers: percutaneous permeation studies for cosmeceutical applications. Colloids Surf B Biointerfaces. 2014;114:144–149.
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172:33–70.
   Web of Science ®Google Scholar
• Albert J, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665–685.
   PubMed Web of Science ®Google Scholar
• Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012;163:34–45.
   PubMed Web of Science ®Google Scholar
• Santos DKF, Rufino RD, Luna JM, et al. Biosurfactants: multifunctional biomolecules of the 21st century. IJMS. 2016;17:401.
   Web of Science ®Google Scholar
• Ullah S, Shah MR, Shoaib M, et al. Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. Drug Deliv. 2016;23:3480–3491.
   PubMed Web of Science ®Google Scholar
• Constantinides PP, Han J, Davis SS. Advances in the use of tocols as drug delivery vehicles. Pharm Res. 2006;23:243–255.
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Mussi SV, Gomes DA, et al. α-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2016;140:246–253.
   PubMed Web of Science ®Google Scholar
• Morakul B, Suksiriworapong J, Leanpolchareanchai J, et al. Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability. Int J Pharm. 2013;457:187–196.
   PubMed Web of Science ®Google Scholar
• Shilakari Asthana G, Sharma PK, Asthana A. In vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin. Scientifica. 2016;2016:6492953.
   PubMed Web of Science ®Google Scholar
• Gupta M, Vaidya B, Mishra N, et al. Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery. Artif Cells Blood Substitutes Biotechnol. 2011;39:376–384.
   PubMed Web of Science ®Google Scholar
• Liang R, Chen L, Yokoyama W, et al. Niosomes consisting of Tween-60 and cholesterol improve the chemical stability and antioxidant activity of (-)-epigallocatechin gallate under intestinal tract conditions. J Agric Food Chem. 2016;64:9180–9188.
   PubMed Web of Science ®Google Scholar
• Cenni E, Granchi D, Avnet S, et al. Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate . Biomaterials. 2008;29:1400–1411.
   PubMed Web of Science ®Google Scholar
• Akuodor G, Usman MI, Ibrahim J, et al. Anti-nociceptive, anti-inflammatory and antipyretic effects of the methanolic extract of Bombax buonopozense leaves in rats and mice. Afr J Biotechnol. 2011;10:3191–3196.
   Google Scholar
• Essa E. Effect of formulation and processing variables on the particle size of sorbitan monopalmitate niosomes. Asian J Pharm. 2010;4:227.
   Google Scholar
• Szoka F, Milholland D, Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1987;31:421–429.
   PubMed Web of Science ®Google Scholar
• Nagayasu A, Shimooka T, Kinouchi Y, et al. Effects of fluidity and vesicle size on antitumor activity and myelosuppressive activity of liposomes loaded with daunorubicin. Biol Pharm Bull. 1994;17:935–939.
   PubMed Web of Science ®Google Scholar
• Shi B, Fang C, Pei Y. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci. 2006;95:1873–1887.
   PubMed Web of Science ®Google Scholar
• Kaur P, Garg T, Rath G, et al. Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design. Drug Deliv. 2014;23:1912–1925.
   PubMed Web of Science ®Google Scholar
• Imran M, Shah MR, Ullah F, et al. Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of cefixime. Int J Pharm. 2016;505:122–132.
   PubMed Web of Science ®Google Scholar
• Müller RH. Colloidal carriers for controlled drug delivery and targeting: modification, characterization and in vivo distribution. Boca Raton (FL): Taylor & Francis, CRC Press; 1991.
   Google Scholar
• Arzani G, Haeri A, Daeihamed M, et al. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomed. 2015;10:4797.
   PubMed Web of Science ®Google Scholar
• GriYn W. Calculation of HLB values of non-ionic surfactants. J Soc Cosmet Chem. 1954;5:249–355.
   Google Scholar
• Ag Seleci D, Seleci M, Walter J-G, et al. Niosomes as nanoparticular drug carriers: fundamentals and recent applications. J Nanomater. 2016;2016:7372306.
   Web of Science ®Google Scholar
• Tao L, Uhrich KE. Novel amphiphilic macromolecules and their in vitro characterization as stabilized micellar drug delivery systems. J Colloid Interface Sci. 2006;298:102–110.
   PubMed Web of Science ®Google Scholar
• Partearroyo MA, Urbaneja M, Goñi FM. Effective detergent/lipid ratios in the solubilization of phosphatidylcholine vesicles by Triton X-100. FEBS Lett. 1992;302:138–140.
   PubMed Web of Science ®Google Scholar
• Amin K, Dannenfelser RM. In vitro hemolysis: guidance for the pharmaceutical scientist. J Pharm Sci. 2006;95:1173–1176.
   PubMed Web of Science ®Google Scholar
• Ménard N, Tsapis N, Poirier C, et al. Drug solubilization and in vitro toxicity evaluation of lipoamino acid surfactants. Int J Pharm. 2012;423:312–320.
   PubMed Web of Science ®Google Scholar
• Kong M, Park H, Feng C, et al. Construction of hyaluronic acid noisome as functional transdermal nanocarrier for tumor therapy. Carbohydr Polym. 2013;94:634–641.
   PubMed Web of Science ®Google Scholar